Psagot Investment House Ltd. lowered its stake in Mazor Robotics Ltd. (NASDAQ:MZOR) by 92.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,118 shares of the medical instruments supplier’s stock after selling 67,445 shares during the quarter. Psagot Investment House Ltd.’s holdings in Mazor Robotics were worth $177,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of MZOR. Gilder Gagnon Howe & Co. LLC acquired a new position in Mazor Robotics in the second quarter valued at about $8,014,000. Nepsis Capital Management Inc. acquired a new position in Mazor Robotics in the second quarter valued at about $5,873,000. Credit Agricole S A acquired a new position in Mazor Robotics in the first quarter valued at about $3,929,000. Credit Suisse AG lifted its position in Mazor Robotics by 66.5% in the first quarter. Credit Suisse AG now owns 330,000 shares of the medical instruments supplier’s stock valued at $9,824,000 after buying an additional 131,804 shares during the last quarter. Finally, Driehaus Capital Management LLC acquired a new position in Mazor Robotics in the first quarter valued at about $3,410,000. 25.92% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Mazor Robotics Ltd. (MZOR) Holdings Reduced by Psagot Investment House Ltd.” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.com-unik.info/2017/10/13/mazor-robotics-ltd-mzor-holdings-reduced-by-psagot-investment-house-ltd.html.
A number of research firms have commented on MZOR. Barclays PLC reaffirmed a “hold” rating and issued a $34.00 target price on shares of Mazor Robotics in a research report on Wednesday. Zacks Investment Research raised shares of Mazor Robotics from a “sell” rating to a “buy” rating and set a $41.00 target price on the stock in a research report on Tuesday, August 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics in a research report on Thursday, July 6th. Finally, Ladenburg Thalmann Financial Services set a $54.00 target price on shares of Mazor Robotics and gave the company a “buy” rating in a research report on Wednesday, August 30th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $37.67.
Shares of Mazor Robotics Ltd. (MZOR) traded up 3.44% during mid-day trading on Friday, hitting $54.10. 163,749 shares of the stock traded hands. The stock has a 50 day moving average price of $47.38 and a 200-day moving average price of $39.22. The company’s market cap is $1.30 billion. Mazor Robotics Ltd. has a one year low of $20.19 and a one year high of $55.66.
Mazor Robotics (NASDAQ:MZOR) last released its quarterly earnings data on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.09. The business had revenue of $15.46 million for the quarter, compared to analyst estimates of $15.38 million. Mazor Robotics had a negative return on equity of 28.51% and a negative net margin of 37.66%. The company’s revenue was up 86.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.09) EPS. On average, analysts forecast that Mazor Robotics Ltd. will post ($0.77) earnings per share for the current fiscal year.
Mazor Robotics Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
What are top analysts saying about Mazor Robotics Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mazor Robotics Ltd. and related companies.